Bone Substudy a Part of Tamoxifen Prevention Trial
PITTSBURGH--A study has begun to determine the effectiveness of tamoxifen (Nolvadex) in preventing osteoporosis in a group of women participating in the Breast Cancer Prevention Trial (BCPT), coordinated by the National Surgical Adjuvant Breast and Bowel Project (NSABP).
PITTSBURGH--A study has begun to determine the effectiveness oftamoxifen (Nolvadex) in preventing osteoporosis in a group ofwomen participating in the Breast Cancer Prevention Trial (BCPT),coordinated by the National Surgical Adjuvant Breast and BowelProject (NSABP).
The Bone Mineral Density and Biochemical Marker Study (BMDS) willinvolve 384 women (half premenopausal and half postmenopausal)randomized to receive tamoxifen or placebo.
The trial will study the effects of tamoxifen on both bone densityand biochemical markers of bone turnover over a period of at least5 years. Data on bone fractures also will be collected on theentire BCPT population of 16,000 women for at least 5 years.
"Most previous studies using tamoxifen have been in animalsor in post-menopausal women with breast cancer, a disease thatitself may affect bone loss," said Normal Wolmark, MD, ofthe NSABP Operations Office.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
The Proper Ways to Identify and Use ADCs in Breast Cancer Subtypes
June 29th 2025Deciding when to use immunotherapy and how to utilize antibody-drug conjugates are complicated processes that require multidisciplinary collaboration to ensure that all patients with breast cancer receive appropriate and efficient care.
Cardio-Oncology Considerations for Breast Cancer: Risk Stratification, Monitoring, and Treatment
June 26th 2025Survivors of breast cancer face increased cardiovascular risks due to treatment-related cardiotoxicity, and understanding these risks is crucial for effective management and prevention.
